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Active site-inactivated factor VIIa prevents
thrombosis without increased surgical bleeding:
Topical and intravenous administration in a rat
model of deep arterial injury
Torbjörn Söderström, MD,a Ulla Hedner MD, PhD,b and Björn Arnljots, MD, PhD,a Malmö, Sweden,
and Bagsvœrd, Denmark
Purpose: The primary event in the procoagulant response after vascular interventions is the tissue factor (TF)–factor
VIIa complex formation, which occurs when TF is exposed to the circulating blood by the inflicted trauma. Human
recombinant active site-inhibited coagulation factor VIIa (FFR-rFVIIa) binds well to TF but cannot initiate blood
coagulation, and should thereby block thrombus formation. This hypothesis was tested with a rat model of arterial
thrombosis.
Methods: In a blinded randomized study, the antithrombotic and antihemostatic effects of FFR-rFVIIa and heparin were
evaluated in a rat model of mechanical deep arterial injury. In one arm of the study, FFR-rFVIIa (0.2 mg in 150 µL)
or vehicle alone was applied topically at the site of vascular injury. In the other arm, FFR-rFVIIa (4 mg/kg), heparin
(1 mg/kg), or vehicle alone was injected intravenously.
Results: FFR-rFVIIa produced a powerful antithrombotic effect after both topical and intravenous administrations (P = .02
and P = .005, respectively) without increasing the surgical bleeding. Heparin prevented thrombosis equally well as FFR-
rFVIIa (P = .0007), but doubled the surgical bleeding compared with FFR-rFVIIa (P = .03) and controls (P = .008). In
the topical study, the antithrombotic effect was achieved without altering parameters of plasma anticoagulation (pro-
thrombin time and activated partial thromboplastin time) or producing detectable levels of FFR-rFVIIa in plasma.
Conclusion: In this model FFR-rFVIIa effectively inhibits thrombus formation without the expense of increased surgi-
cal bleeding, which indicates the potential of FFR-rFVIIa as an effective and safe strategy for prevention of thrombo-
sis in reconstructive vascular surgery and various forms of percutaneous revascularization. (J Vasc Surg
2001;33:1072-9.)
Thrombosis is a serious complication in reconstruc-
tive vascular surgery and diverse forms of balloon
catheter revascularization of arteriosclerotic vessels.1-4
The classic periprocedural antithrombotic regimens,
heparin and aspirin, and newly introduced agents such as
GPIIb-IIIa blockers and hirudin all have the potential of
producing serious bleeding events when given in effec-
tive doses.4-8 Because these hemorrhagic effects relate to
systemic anticoagulation, a logical approach to improve
the safety score of antithrombotic strategies would be to
target the therapy specifically to the treatment site with
a locally active agent.9-12 Ideally, such an agent would
also have a low antihemostatic potential after systemic
delivery and be of endogenous origin, thus avoiding
allergic reactions.
Interventional procedures in blood vessels expose
thrombogenic vascular layers containing tissue factor
(TF) to the blood stream13,14 and rapidly induce TF in
arterial smooth muscle cells.15 TF is a transmembrane
protein that is not normally expressed on the endothe-
lial surface, but is abundant in the adventitia and also in 
the media of blood vessels.13,14 Importantly, TF is also
found in large quantities in arteriosclerotic plaques.14,16,17
It has been shown that TF antigen and activity in arte-
riosclerotic plaques are significantly higher in patients 
with unstable angina and myocardial infarction than in
patients with stable coronary disease.16 Also, in vitro stud-
ies have demonstrated a correlation between platelet
deposition in arteriosclerotic plaques and the amount of
TF.18 These observations are examples of a growing body
of evidence suggesting that TF plays a major role in deter-
mining the thrombus-provoking potential of arterioscle-
rotic lesions.
Thrombus formation in diseased arteries is a thrombin-
mediated and platelet-dependent process; the starting
point of thrombin generation is the formation of a high-
affinity complex between TF and blood coagulation 
factor VIIa (FVIIa). This complex catalyzes the activation
of factor IX to factor IXa and factor X to factor Xa, which
finally cleaves prothrombin to thrombin.19,20 Thrombin is
the key coagulation enzyme, responsible for the conver-
sion of fibrinogen to an adhesive fibrin meshwork, feed-
back amplification of the coagulation processes, and
activation of platelets. In addition, thrombin triggers sev-
eral cellular responses such as mitogenic effect on smooth
muscle cells, ultimately resulting in hyperplasia of the
media and stenosis.21-23
Active site-inactivated FVIIa (FFR-rFVIIa, also
known as ASIS, FVIIai, rVIIai, and rFVIIai) is a modified
form of recombinant human FVIIa (rFVIIa), in which
the enzymatic site has been blocked by a synthetic pro-
tease inhibitor. This yields a substance that binds to TF
with higher affinity than rFVIIa but lacks all procoagu-
lant activity.24 Because FFR-rFVIIa blocks the first step
in the coagulation cascade in the vascular lesion itself, it
is suitable for local administration. We have previously
described antithrombotic effects of locally applied FFR-
rFVIIa,25,26 whereas others have shown effects on
thrombosis and restenosis after systemic administra-
tion.27-31 Notably, these studies have not described hem-
orrhagic effects.25,28,29 These data have suggested the
potential of FFR-rFVIIa as a highly interesting antithrom-
botic agent in context with a variety of percutaneous
revascularization procedures and reconstructive vascular
surgery. In this report, we expand the characterization of
the antithrombotic properties of FFR-rFVIIa with a
thrombosis model in rats that is based on mechanical deep
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arterial injury; we evaluate the antithrombotic effect and
bleeding potential of both local and systemic administra-
tion of FFR-rFVIIa, in comparison with heparin.
METHODS
Thrombosis model
Male Sprague-Dawley white rats with a body weight
(bw) around 400 g (range, 335-482 g) were used. The
experimental procedures were approved by the Research
Ethics Committee, University of Lund, in accordance
with Swedish laws. The rats were anesthetized with a
hypodermal injection of a mixture of fentanyl (0.318
mg/mL, 0.16 mg/kg) and fluanisone (10 mg/mL, 5
mg/kg) (Hypnorm; Janssen Pharmaceutica, Beerse,
Belgium) and midazolam (5 mg/mL, 2.5 mg/kg)
(Dormicum; F. Hoffman-La Roche AG, Basel, Switzer-
land). Anesthesia was maintained with intravenous injec-
tions of fentanyl and fluanisone (0.003-0.01 and 0.1-0.3
mg/kg, respectively). The femoral vessel on one side was
dissected, and a catheter was introduced in the femoral
vein. In the anterior neck region, a caudally based trape-
zoid skin flap was prepared. One centimeter of the left
carotid artery was isolated between vascular clamps, fol-
lowed by longitudinal arteriotomy (5 mm). The vessel
lumen was flattened and pinned up in a rectangular fash-
ion with microneedles; then, a 3-mm long endarterec-
tomy was performed with a scalpel blade, creating a
well-defined injury zone and exposing the adventitia or
deep layers of the media (Fig 1). The depth of the
endarterectomy was confirmed with histology specimens
Fig 1. The endarterectomy procedure.
(Fig 2). The arteriotomy was then closed with a running
10-0 nylon suture (35-45 loops); afterward, the vessel was
reperfused by opening the vascular clamps. Thirty minutes
after reperfusion, vessel patency was assessed with a stan-
dard microvascular empty-refill test, which was performed
in the following manner32: the vessel was occluded distal
to the injury site with a pair of microforceps and emptied
downstream with another pair of forceps. After release of
the first pair of forceps, vessel refilling was assessed, and
the vessel was classed as patent (rapid refilling) or
occluded (no refilling).
In vivo parameters of hemostasis
During the 30 minutes of reperfusion the hemostatic
function was assessed in two ways: (1) the bleeding from
the vessel suture was collected with dry preweighed swabs
and weighed, during which we assessed the total blood
loss by the milligram and (2) to describe the bleeding pat-
tern over time, we observed the suture line every 60th sec-
ond during the 30-minute observation interval for
ongoing bleeding by removing the blood absorbing swab
for a few seconds. A vessel was classed as a bleeding one if
there was any visible bleeding from the suture line. We
made a final observation after the patency test at 31 min-
utes after reperfusion.
JOURNAL OF VASCULAR SURGERY
1074 Söderström, Hedner, and Arnljots May 2001
Preparation of FFR-rFVIIa
FFR-rFVIIa was prepared from rFVIIa as described,33
and its biological characteristics have been outlined else-
where.24 Human FVIIa was purified from culture media
of a transfected baby hamster kidney cell line and inacti-
vated by a molar excess of Phe-Phe-Arg chloromethylke-
tone (Bachem AG, Bubendorf, Switzerland). A surplus of
Phe-Phe-Arg chloromethylketone was separated from
FFR-rFVIIa by ion exchange chromatography. The FFR-
rFVIIa solution was adjusted to a protein concentration of
approximately 2 mg/mL in 10 mmol/L glycylglycine,
150 mmol/L sodium chloride, and pH 7.4 and was ster-
ile filtered. In the topical series, a protein concentration of
1.33 mg/mL was used. The solutions were stored in
aliquots at –80°C.
Experimental protocol
Topical study. Twenty rats were treated with either
FFR-rFVIIa (n = 10) or a vehicle (n = 10). In each rat,
either FFR-rFVIIa (0.2 mg in 150 µL glycylglycine
buffer) or vehicle alone (glycylglycine buffer, 150µL) was
applied drop by drop on the injured vessel segment dur-
ing 3 minutes in a blinded randomized manner.
Afterward, the surplus of the treatment solution was thor-
oughly flushed away with saline, the arteriotomy was
closed, and the vessel was reperfused.
Intravenous study. Thirty rats were treated with
FFR-rFVIIa (n = 10), heparin (n = 10), or a vehicle (n =
10) in a blind random fashion. After the completion of the
vascular injury and vessel suture, an intravenous weight-
adjusted injection of FFR-rFVIIa (4 mg/kg bw), heparin
(1 mg/kg bw), or a vehicle was given for 2 minutes. The
infusion volume was 0.4 mL/100 g bw in all groups. The
vessels were reperfused 3 minutes after injection. Standard
heparin derived from porcine intestinal mucosa was used.
The anticoagulant characteristic of the heparin was 193
anti-Xa units per milligram.
Analysis of FFR-rFVIIa antigen
Plasma levels of FFR-rFVIIa were analyzed with
enzyme-linked immunosorbent assay (FVII enzyme
immunoassay kit with FFR-rFVIIa standard [Dako,
Copenhagen, Denmark]).
Coagulation analyses
Blood (0.9 mL) was drawn from the femoral vein
catheter into plastic syringes containing 0.1 mL of 3.85%
sodium citrate before drug administration, before clamp
release (after drug administration and the completion of
vessel suture), and after the patency test, which was per-
formed 30 minutes after reperfusion. The samples were
centrifuged at 12,000 rpm for 1 minute; afterward, the
plasma was removed and immediately frozen at –70°C.
The prothrombin time (PT) was analyzed with reagents
from Sigma-Aldrich Denmark A/S (Vallensbaek Strand,
Denmark) (topical study) and Dade Behring (Liederbach,
Germany) (intravenous study). The activated partial
thromboplastin time (aPTT) was analyzed with reagents
Fig 2. Cross-sectioned segment of rat carotid artery wall.
Elastica-stain (Orcein) ×1300. Top, Before endarterectomy.
Bottom, After removal of intima and most of the media. The
adventitia and some deep media are exposed.
from Organon Teknika (Boxtel, The Netherlands), by
means of an ACL 300 R automatic analyzer (Instrumenta-
tion Laboratories, Italy); aPTTs were measured for up to
240 seconds.
Statistical methods
Patency rates were compared with Fisher’s exact test
and bleeding volumes with the Mann-Whitney test. For
comparison between the groups of the time dependency
of recurrent arteriotomy bleeding (bleeding pattern), the
30-minute observation interval was divided into three
periods: 1 to 10 minutes, 11 to 20 minutes, and 21 to 30
minutes after reperfusion. In each of these intervals, the
number of bleeding events for each individual vessel was
calculated, and the groups were compared with the Mann-
Whitney test. In regard to the bleeding pattern data in the
intravenous series, overall statistical testing was performed
with the Kruskal-Wallis test. Because of the multiple com-
parisons made in this series, the P values were adjusted
with the Bonferroni method. Bleeding patterns were illus-
trated graphically by the percentage of vessels that was
observed to bleed at each time point in each group. All
statistics were computed on StatXact software (CYTEL
Corp, Cambridge, Mass). Two-sided P values are pre-




Topical application of FFR-FVIIa resulted in a potent
antithrombotic effect. The patency rate was 70% (7/10
vessels) in the FFR-FVIIa group and 10% (1/10 vessels)
in the vehicle group (P = .02) at 30 minutes after vascular
reperfusion (Fig 3, A). In the intravenous series, both
FFR-rFVIIa and heparin produced a pronounced
antithrombotic effect compared with vehicle; the patency
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rate was 100% (10/10) in the heparin group, 90% (9/10)
in the FFR-rFVIIa group, and 20% (2/10) in the vehicle
group. There was a significant difference between the
FFR-rFVIIa and vehicle groups (P = .005) and between
the heparin and vehicle groups (P = .0007), whereas the
FFR-rFVIIa and heparin groups were indistinguishable 
(P = 1) (Fig 3, B).
In vivo parameters of hemostasis
Total surgical bleeding. Topical application of FFR-
rFVIIa did not increase the surgical blood loss compared
with controls. The total surgical bleeding during the 30-
minute observation time was 1.2 mg in the FFR-rFVIIa
group and 1.5 mg in the vehicle group (medians, P = .9)
(Fig 4, A). Likewise, FFR-rFVIIa did not increase the sur-
gical bleeding in the intravenous series. By contrast,
heparin produced a significant total blood loss (1.71 mg)
compared with both vehicle (0.72 mg) and FFR-rFVIIa
(0.86 mg) (medians, P = .008, and P = .03, respectively).
The results are shown in Fig 4, B.
Bleeding pattern. In the topical series, FFR-rFVIIa
significantly increased the number of bleedings from the
Fig 3. Topically applied and intravenously administered FFR-
rFVIIa and heparin produced powerful antithrombotic effects. 
A, Antithrombotic effect after topical application of FFR-rFVIIa
(200 µg) or equal amount of vehicle (n = 10 in both groups). 
B, Antithrombotic effect after intravenous injection of FFR-rFVIIa
(4 mg/kg), heparin (1 mg/kg), or vehicle (n = 10 in each groups).
A B
Fig 4. Surgical bleeding. A, The surgical bleeding was not
affected by topical application of FFR-rFVIIa. B, Intravenous
heparin significantly doubled surgical bleeding, whereas the FFR-
rFVIIa group did not differ from controls. Boxes include 25th,
50th, and 75th percentiles; bars show 10th and 90th percentiles.
A
B
in the diagrams), two of the 10 heparin-treated vessels
were still bleeding, whereas hemostasis was obtained for
all vessels in the vehicle and the FFR-rFVIIa groups.
Plasma analyses
In the topical study, plasma levels of FFR-rFVIIa were
below detection limits, and the aPTT and PT remained at
baseline levels in all rats. In the intravenous series, the
plasma level of FFR-rFVIIa was 0 before injection, 66.5
(48.5-89.0) µg/mL after injection, and 35.3 (27.5-39.7)
µg/mL at the end of experimentation (medians and
ranges) (Fig 6, A), demonstrating a high plasma level of
FFR-rFVIIa during the observation interval. The plasma
half-life of FFR-rFVIIa was approximately 44 minutes,
which is similar to data obtained in rabbits.26 The aPTT
and PT showed consistent, group-specific changes in all
rats; in the heparin group, aPTT after injection was more
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vessels during the first 10 minutes after reflow (P = .001).
However, the number of bleedings attenuated rapidly over
time, and there were no significant differences between
the FFR-rFVIIa and vehicle groups in the last 20 minutes
of observation. Intermittent bleedings beyond 20 minutes
were seen in three of 10 FFR-rFVIIa-treated vessels, but
hemostasis was obtained in all vessels at 26 minutes after
reperfusion (Fig 5, A). The same pattern was found in the
intravenous study, where FFR-rFVIIa and heparin pro-
duced more bleedings than the vehicle did. However, only
heparin significantly increased the number of bleeding
events compared with controls in the first 10-minute
period after reflow (P = .004). Similar to the topical series,
the number of bleedings was not significantly increased in
the periods 11 to 20 and 21 to 30 minutes after reperfu-
sion for either heparin or FFR-rFVIIa (Fig 5, B). It was
noticed that immediately after patency test (at 31 minutes
Fig 5. Bleeding pattern, described as number of nonbleeding vessels at a given time point after reperfusion. The statistical comparison
between the groups is based on number of bleeding events for each individual vessel during three time intervals (1-10, 11-20, and 21-
30 minutes). Significant P values are shown in the graph. A, Topical application of FFR-rFVIIa (200 µg) or vehicle. FFR-rFVIIa signif-
icantly increased number of bleeding vessels during first 10- minute period after reperfusion (P = .001), but not during the second period
(P = .21) or third (P = 1). B, Intravenous injection of FFR-rFVIIa (4 mg/kg), heparin (1 mg/kg), or vehicle. In first 10-minute period,
heparin significantly increased number of bleeding events compared with vehicle (P = .004), whereas FFR-rFVIIa did not (P = .15). All
other comparisons of each 10-minute period were statistically nonsignificant (N.S.).
A B
than 240 seconds, whereas in the FFR-FVIIa group aPTT
values remained at baseline values. PT was affected only in
the FFR-FVIIa group, where it increased from values
between less than 9 and 11.5 seconds before injection to
36.1 seconds (median) at the end of experimentation,
consistent with full plasma anticoagulation (Fig 6, B). 
DISCUSSION
Vascular surgery and balloon catheter angioplasty
involve manipulation or disruption of arteriosclerotic
plaques and deep vascular layers, both of which contain
high levels of TF.13,14,16,17 Because the model used in this
study involves an arterial injury by which vessel layers with
a high TF content are exposed to the blood stream,13,14 it
provides a relevant experimental setup for exploring strate-
gies for the prevention of thrombosis as a complication of
angioplasty and other vascular interventions. The vascular
injury is well defined geometrically, which we think is
important in a model of experimental thrombosis. Because
the model also involves surgical opening and resuturing of
high-flow vessels, hemorrhagic effects of antithrombotic
agents can also be assessed. The model is essentially a
replica of a well-characterized rabbit model of arterial
thrombosis, which has been in use in our laboratory for
many years, and by which several antithrombotic strategies
have been investigated.25,34-38
In this study we demonstrated that FFR-rFVIIa pro-
duces a pronounced antithrombotic effect without
increasing the blood loss when administered both topically
and intravenously. Moreover, after topical application, the
antithrombotic effect was achieved without any systemic
anticoagulation or detectable plasma levels of FFR-rFVIIa.
Our data agree with previous findings in rabbits and
baboons,25-29 albeit with certain interspecies differences as
to the effects of FFR-rFVIIa in the hemostatic system:
intravenously administered FFR-rFVIIa prevented throm-
bus formation in a baboon model of arterial thrombo-
sis,28,29 but was ineffective in rabbits.25 By contrast,
FFR-rFVIIa was highly effective in rabbits when applied
topically25,26 or when infused near the thrombogenic
site27 (that is, administration modes that give high con-
centrations of FFR-rFVIIa at the injury site). Presumably,
the human FFR-rFVIIa interacts better with baboon than
with rabbit TF because of a higher degree of similarity
between the baboon and human hemostatic systems. Such
species-specific interactions may also explain why the same
intravenous doses and plasma concentrations of FFR-
rFVIIa produced a potent antithrombotic effect in our rat
model but not in the similar rabbit model we used previ-
ously.25 Nevertheless, all available experimental data show
that FFR-rFVIIa, pending the mode of administration, is
a highly effective antithrombotic agent. Because FFR-
rFVIIa is of human origin, its antithrombotic effect may
be expected to be at least as good in humans. Thus, topi-
cally applied FFR-rFVIIa is an attractive tool to assess in
clinical vascular interventions, especially when there is
manipulation of arteriosclerotic vessels where the TF con-
tent is known to be high.14,16,17
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The experimental period in this study was half an
hour, which is a short period of time in the context of clin-
ical vascular interventions, where the possibility of sus-
tained thrombogenicity over time due to induction of TF
production in the smooth muscle cells15 and subsequent
reparative processes potentially resulting in restenosis need
to be considered. To this end, the following findings are
of interest. First, we have in vitro data from both human
and rabbit arteries showing that FFR-rFVIIa binds to TF
for 48 hours,39 implying that even a single periprocedural
treatment with FFR-rFVIIa would cover the most critical
postintervention period with regard to thrombotic events.
Moreover, Harker et al30 have demonstrated that a bolus
injection of 5 mg/kg of FFR-rFVIIa followed by a low-
dose infusion for 1 week prevents restenosis at 30 days in
baboons. Similarly, Oltrona et al40 have found that inhibi-
tion of TF-mediated coagulation with a bolus and a low-
dose infusion for 24 hours of tissue factor pathway
inhibitor drastically reduces lesion formation at 4 weeks,
Fig 6. Plasma samples from rats receiving intravenous FFR-
rFVIIa (4 mg/kg): 0, before injection; 1, at time of vascular
reperfusion; and 2, after patency test 30 minutes after reperfusion.
A, Plasma levels of FFR-rFVIIa. B, PT. Three 0 samples showed
values < 9 seconds; these are plotted arbitrarily (asterisk).
A
B
and Golino et al27 have shown in a rabbit arterial throm-
bosis model that the antithrombotic effect does persist
after plasma levels of FFR-rFVIIa have reached baseline
values. Interestingly, Jang et al,31 using specific inhibitors
on different levels of the coagulation cascade, found that
only inactivated FVIIa and tissue activated pathway
inhibitor significantly decreased restenosis. These data
demonstrate that transient inhibition of TF prevents both
thrombosis and restenosis in animal models.
The main parameter of in vivo hemostatic functions in
this study is the surgical blood loss. FFR-rFVIIa did not
increase surgical bleeding compared with controls, either
when applied locally in high concentrations or when given
intravenously in large doses, although the PT values
showed full plasma anticoagulation in the intravenous
series. By contrast, intravenous heparin significantly dou-
bled bleeding volumes versus controls and FFR-
rFVIIa–treated animals. The doses of heparin used in our
study are similar to those commonly used to prevent arte-
rial thrombosis in animal experimentation38,41,42 and to
those used in clinical practice.3-5,43 Also, we have shown
that a reduction of the heparin dose below 1 mg/kg
results in a loss of antithrombotic effect in this model
(unpublished data). Thus, the increased bleeding cannot
be accounted for by an excessively high heparin dosage.
Our current data are compatible with previous findings in
baboons showing that FFR-rFVIIa in antithrombotic
doses does not increase the surgical bleeding, in contrast
to several other specific inhibitors of hemostatic pro-
cesses.28,29
In addition to measuring the surgical blood loss, we
also detected recurrent bleeding over time as a sensitive
parameter of hemostatic plug formation. These measure-
ments demonstrate a mild antihemostatic effect induced
by FFR-rFVIIa and manifested as an intermittent low-vol-
ume leakage of blood through the sutured arteriotomy
slits. However, this leakage attenuated rapidly over time,
and hemostasis was achieved at the end of the experiment
in all vessels. Analogous to measurements of surgical
bleeding, heparin but not FFR-rFVIIa significantly
increased the number of bleeding vessels during the first
10 minutes after reflow in the intravenous series. Although
it can be argued that our recordings of minute arteriotomy
leakage in a high-flow system such as the carotid artery are
overly sensitive and not clinically relevant because bleed-
ing volume was not increased, they illustrate the well-
established notion that antithrombotic efficacy inevitably
implies interference with hemostatic function. However,
these and other experimental data suggest that the antihe-
mostatic potential of FFR-rFVIIa is exceptionally
low,25,28,29 which indicates that FFR-rFVIIa can be used
safely in context with balloon catheter angioplasty and var-
ious forms of vascular surgery. Furthermore, because FFR-
rFVIIa and FVII(a) compete for the same binding sites in
the TF molecule, potential adverse effects of FFR-rFVIIa
can be reversed by the administration of rFVIIa.27
Ideal properties of a substance suitable for prevention
of thrombosis in vascular interventions are high anti-
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thrombotic potency, site-specific effect, low antihemosta-
tic potential, and, preferably, endogenous origin, which
avoids or minimizes allergic reactions. On the basis of
experimentation performed so far, FFR-rFVIIa seems to
satisfy these criteria, making it attractive as an antithrom-
botic agent in humans in context with percutaneous revas-
cularization and reconstructive vascular surgery, especially
in the setting of local drug delivery.
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